HTG Molecular Diagnostics, Firalis Partner on NGS-Based RA Theranostic | GenomeWeb

NEW YORK (GenomeWeb) – HTG Molecular Diagnostics and French biotechnology firm Firalis announced yesterday that they have formed a partnership to develop a next-generation sequencing-based assay for identifying rheumatoid arthritis (RA) patients like to respond to anti-TNF-alpha therapies.

Called RABIOPRED, the assay was developed through a EU-funded project led by French personalized medicine firm Tc Land Expression and Firalis. It is based on a gene-expression panel that includes more than 2,100 microRNAs and runs on HTG's EdgeSeq platform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.

Feb
23
Sponsored by
NuGEN

This webinar will discuss a project that sought to understand the parent-of-origin epigenetic mechanisms that regulate seed development in plants, with a particular emphasis on differentiating the maternal or paternal origin of epigenetics marks.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV. 

Mar
16
Sponsored by
Agilent Technologies

This online seminar will discuss how improvements on the front end and back end of the sequencing workflow can lead to better RNA-seq results.